Compass Therapeutics Inc. Cash Flow-to-Debt Ratio
Compass Therapeutics Inc. cash flow-to-debt ratio. Compass Therapeutics Inc. (CMPX) has a Cash Flow-to-Debt Ratio of -0.56x as of June 2026, meaning its operating cash flow of $-13.42 Million could theoretically repay -1% of its total liabilities ($24.12 Million) in one year. See CMPX free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Compass Therapeutics Inc. (2018–2025)
Cash flow-to-debt ratio of Compass Therapeutics Inc. from 2018 to 2025. Historical debt coverage capacity for Compass Therapeutics Inc. across 8 annual periods. See CMPX equity to assets ratio to measure how much of total assets are equity-financed.
Compass Therapeutics Inc. Cash Flow-to-Debt Ratio by Year (2018–2025)
Compass Therapeutics Inc. cash flow-to-debt ratio by year from 2018 to 2025. Year-by-year debt coverage analysis for Compass Therapeutics Inc.. For the full cash flow conversion analysis, see CMPX cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.16x | $-49.14 Million | $22.80 Million | ▲ +27.1% |
| 2024 | -2.96x | $-44.85 Million | $15.17 Million | ▲ +39.3% |
| 2023 | -4.87x | $-40.62 Million | $8.34 Million | ▼ -157.1% |
| 2022 | -1.90x | $-34.12 Million | $18.01 Million | ▼ -31.8% |
| 2021 | -1.44x | $-19.67 Million | $13.68 Million | ▲ +35.8% |
| 2020 | -2.24x | $-26.80 Million | $11.97 Million | ▼ -951.4% |
| 2019 | -0.21x | $-31.74 Million | $148.98 Million | ▲ +5.5% |
| 2018 | -0.23x | $-33.68 Million | $149.40 Million | — |